

# Sabina Sangaletti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/979716/sabina-sangaletti-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57  
papers

3,778  
citations

30  
h-index

61  
g-index

69  
ext. papers

4,470  
ext. citations

9.3  
avg. IF

4.97  
L-index

#	Paper	IF	Citations
57	Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. <i>Cellular Immunology</i> , <b>2021</b> , 362, 104301	4.4	0
56	Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 2429-2438	7.4	3
55	CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 662048	8.4	0
54	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 825-837	12.5	1
53	SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis. <i>IScience</i> , <b>2021</b> , 24, 102510	6.1	1
52	A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis. <i>Molecular Oncology</i> , <b>2021</b> , 15, 1345-1357	7.9	2
51	Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. <i>Journal of Molecular Medicine</i> , <b>2020</b> , 98, 595-612	5.5	13
50	Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. <i>EBioMedicine</i> , <b>2020</b> , 61, 103055	8.8	7
49	Transcriptional Profiles and Stromal Changes Reveal Bone Marrow Adaptation to Early Breast Cancer in Association with Deregulated Circulating microRNAs. <i>Cancer Research</i> , <b>2020</b> , 80, 484-498	10.1	8
48	Tumor-Derived Prostaglandin E2 Promotes p50 NF- $\kappa$ B-Dependent Differentiation of Monocytic MDSCs. <i>Cancer Research</i> , <b>2020</b> , 80, 2874-2888	10.1	42
47	WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. <i>Oncogene</i> , <b>2019</b> , 38, 4047-4060	9.2	101
46	The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. <i>Oncogene</i> , <b>2019</b> , 38, 3636-3650	9.2	87
45	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. <i>Cancers</i> , <b>2019</b> , 11,	6.6	22
44	DNA threads released by activated CD4 T lymphocytes provide autocrine costimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 8985-8994	11.5	14
43	SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1369	8.4	30
42	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , <b>2019</b> , 79, 1938-1951	10.1	33
41	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 989-999	12.8	213

40	Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 552-565	12.5	31
39	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	7
38	Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer. <i>Journal of Leukocyte Biology</i> , <b>2017</b> , 102, 287-292	6.5	13
37	Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 1059-1067	7.4	23
36	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. <i>Cancer Research</i> , <b>2017</b> , 77, 3685-3699	10.1	16
35	Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5149-5161	12.9	37
34	The good and bad of targeting cancer-associated extracellular matrix. <i>Current Opinion in Pharmacology</i> , <b>2017</b> , 35, 75-82	5.1	13
33	Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. <i>FASEB Journal</i> , <b>2017</b> , 31, 5356-5370	0.9	7
32	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1918	8.4	55
31	Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. <i>Oncotarget</i> , <b>2016</b> , 7, 3905-20	3.3	6
30	Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. <i>Cell Reports</i> , <b>2016</b> , 17, 233-248	10.6	62
29	Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth. <i>Cancer Research</i> , <b>2015</b> , 75, 3760-70	10.1	19
28	The ins and outs of osteopontin. <i>Oncolmmunology</i> , <b>2015</b> , 4, e978711	7.2	3
27	SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias. <i>Cancer Research</i> , <b>2015</b> , 75, 2387-99	10.1	28
26	SCD5-induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B. <i>Journal of Pathology</i> , <b>2015</b> , 236, 315-25	9.4	27
25	RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopenesis. <i>Cancer Cell</i> , <b>2015</b> , 28, 253-69	24.3	121
24	Osteopontin shapes immunosuppression in the metastatic niche. <i>Cancer Research</i> , <b>2014</b> , 74, 4706-19	10.1	84
23	Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. <i>Blood</i> , <b>2014</b> , 123, 1836-49	2.2	31

22	Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. <i>Onc Immunology</i> , <b>2014</b> , 3, e28989	7.2	27
21	Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. <i>Cancer Discovery</i> , <b>2014</b> , 4, 110-29	24.4	78
20	Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. <i>Cell Death and Disease</i> , <b>2013</b> , 4, e920	9.8	34
19	Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. <i>Blood</i> , <b>2012</b> , 120, 3541-54	2.2	36
18	Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. <i>Blood</i> , <b>2012</b> , 120, 3007-18	2.2	265
17	Microenvironment-centred dynamics in aggressive B-cell lymphomas. <i>Advances in Hematology</i> , <b>2012</b> , 2012, 138079	1.5	15
16	SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 3000-10	5.8	46
15	The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. <i>Journal of Autoimmunity</i> , <b>2011</b> , 37, 300-10	15.5	22
14	The bone marrow stroma in hematological neoplasms--a guilty bystander. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 456-66	19.4	37
13	Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. <i>Cancer Research</i> , <b>2011</b> , 71, 5987-97	10.1	101
12	Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. <i>Cancer Research</i> , <b>2010</b> , 70, 7764-75	10.1	27
11	Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 2931-42	16.6	149
10	Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. <i>Cancer and Metastasis Reviews</i> , <b>2010</b> , 29, 295-307	9.6	173
9	Matricellular proteins at the crossroad of inflammation and cancer. <i>Cancer Letters</i> , <b>2008</b> , 267, 245-53	9.9	31
8	Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. <i>Cancer Research</i> , <b>2008</b> , 68, 9050-9	10.1	146
7	Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. <i>Cancer Research</i> , <b>2007</b> , 67, 11438-46	10.1	273
6	Triggering CD40 on endothelial cells contributes to tumor growth. <i>Journal of Experimental Medicine</i> , <b>2006</b> , 203, 2441-50	16.6	67
5	Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. <i>Cancer Research</i> , <b>2005</b> , 65, 3437-46	10.1	435

4	Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. <i>Journal of Cell Science</i> , <b>2005</b> , 118, 3685-94	5.3	49
3	Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 198, 1475-85	16.6	116
2	Lipopolysaccharide or whole bacteria block the conversion of inflammatory monocytes into dendritic cells in vivo. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 198, 1253-63	16.6	97
1	Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 3101-10	6.1	17